- A patient is admitted with a new diagnosis of heart failure. The physician's admission orders include lisinopril 10 mg daily. The medication reconciliation reveals the patient is taking losartan 50 mg daily at home. Which of the following describes the relationship between these two medications and the necessary intervention?
Answer: Therapeutic duplication; both are RAAS inhibitors and should not be used concurrently. One must be discontinued.
Lisinopril is an ACE inhibitor and losartan is an angiotensin II receptor blocker (ARB). Both act on the renin-angiotensin-aldosterone system (RAAS). Using them together (therapeutic duplication) is contraindicated as it does not provide additional benefit and significantly increases the risk of adverse effects like hyperkalemia, hypotension, and acute kidney injury. The pharmacist must contact the prescriber to clarify which agent should be continued and ensure the other is discontinued.
- During medication reconciliation, which potential issue warrants the most immediate clarification with the prescribing physician?
Answer: The therapeutic duplication of two NSAIDs (ibuprofen and ketorolac), increasing the risk of gastrointestinal bleeding and nephrotoxicity.
The most significant and immediate issue is the therapeutic duplication of two potent NSAIDs. Both ibuprofen and ketorolac inhibit cyclooxygenase, and their concurrent use significantly increases the risk for acute kidney injury and gastrointestinal bleeding, especially in an older adult. This risk outweighs the other potential issues.
- During medication review, what is the most appropriate action for the pharmacist to take?
Answer: Contact the physician to further clarify the nature of the childhood allergic reaction and discuss the low cross-reactivity between penicillins and carbapenems.
The best action is to gather more information. A history of a non-anaphylactic rash in childhood has a very low probability of representing a true, current IgE-mediated allergy. However, the pharmacist cannot unilaterally decide this. The most appropriate step is to engage the prescriber, clarify the allergy history, and discuss the risks/benefits. Broad-spectrum agents like meropenem should be avoided if a narrower-spectrum, first-line agent could be used safely. This promotes antimicrobial stewardship while ensuring patient safety.
- The patient's new symptoms are most likely the result of which drug interaction?
Answer: A pharmacodynamic interaction resulting from the combined serotonergic activity of sertraline, trazodone, and tramadol.
The patient's clinical presentation with agitation, confusion, diaphoresis, and myoclonus (tremor) is classic for serotonin syndrome. This is a pharmacodynamic interaction caused by excessive serotonin levels. Sertraline (an SSRI), trazodone (a serotonin antagonist and reuptake inhibitor), and tramadol (a weak serotonin reuptake inhibitor) all increase serotonergic activity. Their combination puts the patient at high risk for this syndrome.
- When screening for potential drug interactions upon admission, which of the following requires the most urgent management?
Answer: Albuterol can cause hypokalemia, increasing the risk of digoxin toxicity.
While all listed points are valid concerns, the interaction between albuterol and digoxin is the most urgent. High doses of beta-2 agonists like albuterol can cause a significant intracellular shift of potassium, leading to hypokalemia. Hypokalemia markedly sensitizes the myocardium to digoxin, increasing the risk of life-threatening arrhythmias even with a therapeutic digoxin level. This acute risk requires immediate monitoring and possible potassium supplementation.
- Which component of this bridging plan requires intervention during the medication reconciliation process?
Answer: The last dose of therapeutic enoxaparin should be administered approximately 24 hours before the surgical incision.
For patients on therapeutic doses of LMWH (like 1 mg/kg BID), the last dose should be given at least 24 hours prior to surgery to minimize the risk of major perioperative bleeding, especially with neuraxial anesthesia. Administering a full therapeutic dose on the morning of surgery is a significant safety error. The timing of the last dose is the most critical flaw in this plan.
- Which herbal supplement is the most likely cause of the patient's subtherapeutic INR?
Answer: St. John's Wort
St. John's Wort is a potent inducer of the cytochrome P450 enzyme CYP2C9, which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. Induction of this enzyme increases warfarin metabolism, leading to lower serum levels and a decreased anticoagulant effect, resulting in a subtherapeutic INR. Ginkgo and garlic can increase bleeding risk (potentiate warfarin), while saw palmetto has no significant documented interaction.
- The patient's elevated blood pressure is most likely due to an interaction in which the over-the-counter medication is causing:
Answer: Increased sodium and water retention by inhibiting prostaglandin synthesis in the kidneys.
When you encounter a previously well-controlled hypertensive patient with sudden blood pressure elevation after starting an over-the-counter medication for arthritis, think NSAIDs (nonsteroidal anti-inflammatory drugs) and their renal effects.
NSAIDs like ibuprofen, naproxen, and aspirin work by inhibiting cyclooxygenase (COX) enzymes, which blocks prostaglandin synthesis. In the kidneys, prostaglandins normally promote vasodilation of renal blood vessels and enhance sodium excretion. When NSAIDs block prostaglandin production, you get vasoconstriction of renal vessels and increased sodium and water retention, leading to elevated blood pressure. This mechanism makes option D correct.
Let's examine why the other options don't fit: Option A describes competitive antagonism at angiotensin II receptors - but NSAIDs don't interact with the renin-angiotensin system at the receptor level, and lisinopril is an ACE inhibitor, not an ARB. Option B suggests drug metabolism induction, but NSAIDs don't significantly induce the cytochrome P450 enzymes that metabolize lisinopril. Option C proposes direct alpha-adrenergic agonism, but NSAIDs don't have direct sympathomimetic effects on adrenergic receptors.
For pharmacology exams, remember this key pattern: when you see hypertension worsening after starting NSAIDs, the mechanism is always renal - prostaglandin inhibition leads to sodium retention and vasoconstriction. This interaction is especially important in patients on ACE inhibitors or ARBs, as both drug classes depend partly on prostaglandin-mediated effects for optimal blood pressure control.
- Based on the medication reconciliation, which of the following is the MOST critical counseling point to prevent a medication error by the patient at home?
Answer: Explain that the patient should dispose of his old furosemide 20 mg tablets and only take the new 40 mg tablets.
A common and dangerous error after discharge is for patients to continue taking old medications along with new ones. In this case, if the patient takes his old furosemide 20 mg tablets in addition to the new 40 mg prescription, he would be taking 60 mg daily, risking dehydration and electrolyte abnormalities. Explicitly instructing him to discard the old supply of the changed medication is the most direct way to prevent this specific reconciliation-related error.
- To obtain the Best Possible Medication History (BPMH) in this scenario, which of the following actions should the pharmacist prioritize?
Answer: Call the patient's outpatient community pharmacy to obtain a fill history for the last 6-12 months.
While all sources provide some information, the most reliable and comprehensive source in this complex situation is the patient's outpatient pharmacy fill history. This will provide drug names, strengths, dosages, fill dates, and quantities, which is crucial for constructing an accurate BPMH. Pill identification (A) is useful but doesn't confirm adherence or dosage. The daughter's list (C) is a good starting point but she admits uncertainty. The last discharge summary (D) may be outdated.
- Failure to address this discrepancy during the intra-hospital transfer reconciliation process places the patient at highest immediate risk for what outcome?
Answer: Severe iatrogenic hypoglycemia
This scenario describes a classic medication reconciliation error during an internal transfer. If the continuous IV insulin infusion is not stopped when the new subcutaneous regimen (which includes basal insulin) is started, the patient will receive overlapping insulin doses. This therapeutic duplication will almost certainly lead to severe and potentially fatal hypoglycemia. This is the most immediate and life-threatening risk.
- As the pharmacist reviewing this order, what is the most urgent potential drug interaction that must be addressed?
Answer: Clarithromycin is a potent CYP3A4 inhibitor and will significantly increase serum tacrolimus concentrations, leading to a high risk of toxicity.
Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index, and it is primarily metabolized by CYP3A4. Clarithromycin is a potent inhibitor of CYP3A4. Co-administration will lead to a rapid and significant increase in tacrolimus levels, placing the patient at high risk for severe nephrotoxicity and neurotoxicity. This interaction is more immediate and life-threatening than the other concerns.
- The patient's presentation is most likely due to a pharmacodynamic interaction between citalopram and ciprofloxacin, which results in:
Answer: An additive effect on QT interval prolongation.
When you encounter a question about drug interactions causing cardiac effects, first determine whether it's a pharmacokinetic interaction (affecting drug levels) or pharmacodynamic interaction (affecting drug effects at the target). The question stem explicitly tells you this is a pharmacodynamic interaction.
Both citalopram (an SSRI) and ciprofloxacin (a fluoroquinolone antibiotic) are known to independently prolong the QT interval by blocking cardiac potassium channels, specifically the hERG channel. When used together, their effects are additive - meaning each drug contributes its own QT-prolonging effect, resulting in a combined effect greater than either drug alone. This additive pharmacodynamic interaction explains the patient's prolonged QTc of 510 ms and subsequent palpitations.
Looking at the wrong answers: Option A is incorrect because ciprofloxacin doesn't act alone here - both drugs contribute to potassium channel blockade. Option B describes a pharmacokinetic interaction involving drug metabolism, but the question specifically states this is a pharmacodynamic interaction, and ciprofloxacin doesn't significantly inhibit the CYP enzymes that metabolize citalopram. Option C is wrong because serotonin syndrome results from excessive serotonergic activity, not QT prolongation, and ciprofloxacin doesn't affect serotonin pathways.
The correct answer is D - the additive effect occurs because both drugs independently block the same cardiac ion channels.
Study tip: Remember that QT prolongation is a class effect of both SSRIs and fluoroquinolones. When you see these drug classes combined with cardiac symptoms, think additive pharmacodynamic effects rather than metabolic interactions.
- What is the most appropriate first step for the pharmacist to take to resolve this discrepancy?
Answer: Contact the prescriber to verify whether the change was intentional, for example, due to hospital formulary.
Pharmacists cannot unilaterally change a physician's order. The discrepancy could be an error, or it could be an intentional change (e.g., due to formulary restrictions, a new contraindication, or provider preference). The only way to know is to communicate with the prescriber. This first step clarifies intent, ensures patient safety, and allows for correction if the change was indeed an error.
- The initiation of carvedilol in this patient represents what type of medication-related problem?
Answer: A drug-disease interaction, as non-selective beta-blockers are relatively contraindicated in patients with severe asthma.
This is a classic drug-disease interaction. Carvedilol is a non-selective beta-blocker (blocks β1 and β2 receptors). Blocking β2 receptors in the lungs can cause bronchoconstriction and antagonize the effects of beta-agonists, potentially leading to a severe asthma exacerbation. While it also represents a pharmacodynamic drug-drug interaction (A), the more fundamental problem is using this class of drug in this specific disease state.
- Upon reviewing the discharge medication list as part of the medication reconciliation process, which of the following represents the most critical, time-sensitive intervention for the pharmacist to make?
Answer: Contact the prescriber to recommend adding a prescription for bridging anticoagulation with a low-molecular-weight heparin.
The most critical issue is the lack of bridging anticoagulation. Warfarin has a slow onset of action, and a therapeutic INR (typically 2.0-3.0) will not be reached for several days. An INR of 1.6 is subtherapeutic. Discharging the patient on warfarin alone without a bridging agent like enoxaparin creates a high risk for thrombosis. This is a critical omission that requires immediate correction.
- If this look-alike/sound-alike discrepancy is not identified and corrected, what is the most likely clinical consequence for the patient?
Answer: Uncontrolled hypertension due to the omission of his antihypertensive and administration of an antihistamine.
This is a classic look-alike/sound-alike (LASA) error. Hydralazine is a vasodilator used for hypertension. Hydroxyzine is a first-generation antihistamine with sedative and anxiolytic properties. If the error is not caught, the patient will not receive his prescribed antihypertensive (hydralazine), leading to uncontrolled hypertension. He will instead receive an antihistamine (hydroxyzine), which does not treat hypertension.
- How should the pharmacist best classify and address this medication reconciliation discrepancy?
Answer: This is an unintentional discrepancy; the prescriber should be contacted to hold or dose-adjust the metformin due to the risk of lactic acidosis.
This is a critical, unintentional discrepancy. Metformin is contraindicated in patients with significantly reduced renal function (e.g., eGFR < 30 mL/min) due to the increased risk of accumulation and life-threatening lactic acidosis. Continuing the home dose in the setting of AKI is a serious error. The appropriate action is to recognize it as unintentional and immediately contact the prescriber to recommend holding or appropriately adjusting the dose.
